🔍 BioSolution Designs (BSD) and RoosterBio are collaborating to simplify the development of engineered MSC-derived therapies.
🤝 The partnership combines BSD’s Bird of Prey platform and cell engineering expertise with RoosterBio’s bioprocessing products and manufacturing protocols.
💡 The goal is to provide an end-to-end solution for the engineering and development of cell- and exosome-based therapeutics.
👨🔬 This collaboration will benefit both companies and accelerate the progression of next-generation therapeutics.
🤝 The partnership combines BSD’s Bird of Prey platform and cell engineering expertise with RoosterBio’s bioprocessing products and manufacturing protocols.
💡 The goal is to provide an end-to-end solution for the engineering and development of cell- and exosome-based therapeutics.
👨🔬 This collaboration will benefit both companies and accelerate the progression of next-generation therapeutics.
📢 Revolutionary Partnership Simplifies MSC Therapy Development
Introduction:
BioSolution Designs (BSD) and RoosterBio have announced a collaboration to simplify the development and manufacturing of engineered human mesenchymal stem/stromal cell (MSC)-derived therapies. The partnership aims to provide an end-to-end solution for the engineering and development of cell- and exosome-based therapeutics.
Main points:
- BioSolution Designs and RoosterBio are collaborating to facilitate the development and manufacturing of engineered human MSC-derived therapies.
- The partnership combines BSD’s multigenic design and assembly platform, Bird of Prey, with RoosterBio’s MSC and exosome bioprocessing products, manufacturing protocols, and analytical services.
- The goal is to accelerate the clinical progression of cell and exosome therapeutics by combining innovative multigenic technologies with well-established cell therapy products and scalable bioprocess manufacturing platforms.
Conclusion:
The collaboration between BioSolution Designs and RoosterBio aims to provide a seamless solution for the engineering and development of cell- and exosome-based therapeutics. By leveraging their respective expertise and technologies, they hope to accelerate the clinical progression of the next generation of cell and exosome therapies.
